ArticleMedicine2026
Potential therapeutic targets for multisite chronic pain: A proteome-wide Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multisite chronic pain (MCP) is a complex and increasingly prevalent health issue that significantly impairs quality of life. This study aims to identify potential therapeutic targets for MCP through a proteome-wide Mendelian randomization (MR) approach. We conducted a proteome-wide MR to explore the causal associations of plasma proteins with MCP. MCP used data from a genome-wide association study including 387,649 samples. We used protein data from UKB-PPP including 54,219 samples as the discovery analysis, and from Finngen as the replication analysis. Multiple follow-up analyses were used to investigate the potential function of the candidate proteins. Finally, druggability evaluation and phenome-wide MR analysis were used to assess the priority of these targets. We identified 11 plasma proteins significantly associated with MCP. Increased levels of LRP11, BCHE, DAG1, and SUOX exhibited protective effects, while LATS1, CEP170, SLC27A4, HEXIM1, ECM1, C8B, and MST1 increased MCP risk. After multiple validations, ECM1, C8B, LRP11, BCHE has the strongest convincing evidence. Besides, mediation analysis found 4 reliable combinations, revealed the role of plasma proteins in traits influencing MCP. Finally, druggability evaluation and phenome-wide MR indicated that C8B, and BCHE had the highest priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.